NCT02228525View on ClinicalTrials.gov

Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 27, 2014

Primary Completion Date

April 6, 2021

Study Completion Date

April 6, 2021

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

selinexor (KPT-330)

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors
All Listed Sponsors
collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

Columbia University

OTHER

collaborator

Karyopharm Therapeutics Inc

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER